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Background and aims
In the Netherlands, off-label prescription of medicines is
tolerated as a suboptimal but inevitable practice. However,
patients with rare diseases are disadvantaged in claiming
reimbursement for off-label or off-license drugs (here
summarised as ‘off-label’). It is difficult to meet the burden
of evidence-based proof on efficacy of such medicines.
Consensus-based guidelines, a second-best but accepted
form of evidence, are also often lacking. Both industry and
academia are challenged to perform classical randomized,
controlled trials for rare diseases. Moreover, reimburse-
ment rules discourage doctors from prescribing medicines
off-label, even to small groups of patients. Thus there is an
impasse to creating evidence. Conditionally reimbursed,
controlled n-of-one (single-patient) trials with internal
randomisation (e.g. AB-BA-BA) could generate evidence
on efficacy for rare, chronic conditions where the aim of
treatment is symptom control. Practical and scientific sup-
port might be provided by a dedicated trial service.
This project aims to initiate development of an n-of-one
trial service, embedded in the Dutch health care system,
for research on efficacy and safety of certain medicines
with no marketing authorisation for the rare diseases for
which they are prescribed.
Methods and preliminary results
Reimbursement problems with off-label medicines were
inventoried among neuromuscular specialists and patients
with neuromuscular disease. This list was prioritized for
medicines and indications suitable for n=1-trials. Two
cases were selected for systematic literature review and
development of clinical protocols for n-of-one trials.
A multidisciplinary expert meeting defined the legal, ethi-
cal and scientific preconditions for starting an n-of-one
trial service. Recommendations were made for performing
n-of-one research in a scientifically sound and socially
robust manner.
Regulatory authorities and insurers may accept evidence
from n-of-one trials, provided that data can be aggregated
and that benefit/risk ratio is considered. An n-of-one trial
service may be justified, if it can support a broad range of
rare diseases.
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